Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for BRAF V600E-mutant non-small-cell lung cancer, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No randomised trial compares BRAF plus MEK inhibitors with chemoimmunotherapy first line or settles the sequence.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Non-V600 BRAF mutations, half of cases, have no approved targeted therapy.
Resistance through MAPK reactivation has no established next step.
Nothing recorded yet.
Nothing recorded yet.
Background: Drug resistance (primary and acquired). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
BRAF V600E NSCLC with binimetinib
Response rate 75% (treatment-naive, n=59) and 46% (previously treated, n=39); FDA approval October 2023.
A milestone in how this cancer is treated.
Confirmed objective response 64 percent (23 of 36), with 6 percent complete responses; grade 3 or worse adverse events in 69 percent.
A milestone in how this cancer is treated.